QNNT.F Stock Overview
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Quantum Genomics Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.10 |
| 52 Week High | €0.10 |
| 52 Week Low | €0.10 |
| Beta | 0.66 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| QNNT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | 0.6% |
| 1Y | n/a | 2.7% | 25.7% |
Return vs Industry: Insufficient data to determine how QNNT.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how QNNT.F performed against the US Market.
Price Volatility
| QNNT.F volatility | |
|---|---|
| QNNT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: QNNT.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine QNNT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 3 | Jean-Philippe Milon | www.quantum-genomics.com |
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs.
Quantum Genomics Société Anonyme Fundamentals Summary
| QNNT.F fundamental statistics | |
|---|---|
| Market cap | US$4.96m |
| Earnings (TTM) | -US$3.42m |
| Revenue (TTM) | US$21.33k |
232.4x
P/S Ratio-1.5x
P/E RatioIs QNNT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QNNT.F income statement (TTM) | |
|---|---|
| Revenue | €19.80k |
| Cost of Revenue | €1.44m |
| Gross Profit | -€1.42m |
| Other Expenses | €1.75m |
| Earnings | -€3.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.091 |
| Gross Margin | -7,169.57% |
| Net Profit Margin | -16,018.12% |
| Debt/Equity Ratio | 622.2% |
How did QNNT.F perform over the long term?
See historical performance and comparison